Editas Medicine (EDIT) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.76 per share a year ago. These figures are ...
Editas Medicine EDIT reported new positive data from the phase I/II/III RUBY study of its lead candidate, reni-cel, in 18 patients with sickle cell disease (SCD) and the phase I/II EdiTHAL study of ...
Gov. Andrew Cuomo allegedly himself “edited” a state report that deflated New York’s COVID-19 death toll in nursing homes — which his top aides pressured health officials into releasing, despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback